AQST Aquestive Therapeutics

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
EN
14/10/2020

Underlying

AQSTAquestive Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics...

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host 1x1 investor meetings on July 9, 2025. The forum will include panels exploring key th...

July 7, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic a...

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the tr...

June 25, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces FDA Acceptance of New Drug Applicatio...

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (N...

June 16, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Reports First Quarter 2025 Financial Results an...

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to pa...

May 12, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in Citizens Life Sciences Confer...

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting one-on...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch